IH 764-3 (764-3)

12/01/2012 - " The monomer IH764-3 ameliorates experimental liver fibrosis by inhibiting HSC proliferation and inducing HSC apoptosis, warranting its use as a potential therapeutic agent in the treatment of liver fibrosis."
12/01/2012 - " Moreover, the results revealed that IH764-3 downregulated the expression levels of FAK, p-FAK (Tyr397), ERK and p-ERK in the liver tissue of rats with liver fibrosis. "
12/01/2012 - "In the current study, we used a rat model of liver fibrosis induced by bile duct ligation (BDL) to investigate the effect of the monomer IH764-3 on the induction of apoptosis in HSCs in vivo. "
12/01/2012 - "The Salvia miltiorrhiza monomer IH764-3 induces apoptosis of hepatic stellate cells in vivo in a bile duct ligation-induced model of liver fibrosis."
12/01/2012 - "The monomer IH764-3 was associated with a significant decrease in intrahepatic fibrogenesis and collagen deposition and attenuated the liver fibrosis induced by BDL. "

09/01/1994 - "764-3 has certain protective effects and may be useful in the treatment of early chronic obstructive pulmonary disease."

03/01/1993 - "Experimental study of the effect of IH764-3 on pulmonary fibrosis."
08/01/1992 - "[Experimental study of the effect of IH764-3, a potent component isolated from salviae milltiorrhize, against pulmonary fibrosis]."
03/01/1993 - "We have studied the effect of IH764-3 on experimental pulmonary fibrosis in rats and mice treated with a single intratracheal instillation of bleomycin-A6. "
08/01/1992 - "IH764-3, an effective component isolated from Salvae milliorrhize (a component of traditional Chinese medicine) was used against pulmonary fibrosis in this study. "
10/01/1994 - "It reports that IH764-3 has both therapeutical and prophylactic effect on bleomycin-induced pulmonary fibrosis in rats and mice. "

02/01/1998 - "764-3 could reduce the raised PAP induced either by hypoxia or MCT. "
02/01/1998 - "The hypobaric hypoxia group received 764-3 20 mg/kg once daily subcutaneously and the MCT group treated with 764-3 40 mg/kg once daily. "
09/01/1994 - "764-3 treatment obviously attenuated most of the changes caused by hypoxia, though it had no effect on compliance of the pulmonary vessels. "
06/01/1998 - "To investigate the effects of an extract of salviae miltiorrhizae (764-3) on the percentage of intra-acinar muscular artery (MA), partal MA(PMA) and nonmuscular MA(NMA) and collagen deposition in the media of MA in rats with hypoxia and MCT-induced pulmonary hypertension. "
06/01/1998 - "[Effects of an extract of salviae miltiorrhizae (764-3) on structural remodeling of intra-acinar pulmonary artery in pulmonary hypertension due to chronic hypoxia and monocrotaline in rats]."

08/01/1996 - "764-3 and ligustrazine may be two hopeful therapeutic drugs for chronic hypoxic pulmonary hypertension."
06/01/1998 - "To investigate the effects of an extract of salviae miltiorrhizae (764-3) on the percentage of intra-acinar muscular artery (MA), partal MA(PMA) and nonmuscular MA(NMA) and collagen deposition in the media of MA in rats with hypoxia and MCT-induced pulmonary hypertension. "
06/01/1998 - "[Effects of an extract of salviae miltiorrhizae (764-3) on structural remodeling of intra-acinar pulmonary artery in pulmonary hypertension due to chronic hypoxia and monocrotaline in rats]."
06/01/1998 - "764-3 can partially inhibit collagen deposition in pulmonary arteries, attenuate hypoxic pulmonary hypertension, and has a moderate influence on collagen deposition in compared with BAPN."
06/01/1998 - "764-3 can partially inhibit collagen deposition in pulmonary arterioles attenuate hypoxia and MCT-induced pulmonary hypertension, reduce the percentage of MA, and has a moderate influence on collagen deposition as compared with BAPN."